ArticleBlood advances2023

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study.

Federica R Achini-Gutzwiller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.